Manipulations of the metabolic response for management of patients with severe surgical illness: Review

World Journal of Surgery

Volumn 24, Issue 6, 2000, Pages 696-704

  Connolly, A B ^a,b   Vernon, D R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b MIDDLEMORE HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BRADYKININ; ENDOTOXIN; GLUCOCORTICOID; GROWTH FACTOR; HLA DR ANTIGEN; HYBRID PROTEIN; INTERFERON; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY; NITRIC OXIDE; PENTOXIFYLLINE; SOMATOMEDIN C; TAUROLIDINE; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

CLINICAL TRIAL; CRITICAL ILLNESS; HUMAN; INJURY; METABOLISM; NUTRITIONAL SUPPORT; REVIEW; SEPSIS;

ANIMALS; GROWTH SUBSTANCES; HUMANS; NUTRITIONAL SUPPORT; PLATELET ACTIVATING FACTOR; SEPSIS; SHOCK, SEPTIC; STRESS; SURGICAL PROCEDURES, OPERATIVE; TUMOR NECROSIS FACTOR-ALPHA; WOUNDS AND INJURIES;

EID: 0034107567     PISSN: 03642313     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002689910112     Document Type: Review

References (75)

1. Plank, L.D., Connolly, A.B., and Hill, G.L.: Sequential changes in the metabolic response in severely septic patients during the first 23 days after the onset of peritonitis. Ann. Surg. 228:146, 1998
2. Lefering, R., and Neugebauer, E.A.M.: Steroid controversy in sepsis and septic shock: a meta-analysis. Crit. Care Med. 23:1294, 1995
3. Cronin, L., Cook, D., Carlet, J., Heyland, D.K., King, D., Lansang, M.A., and Fisher, C.J.: Corticosteroid treatment for sepsis: a clinical appraisal and meta-analysis of the literature. Crit. Care Med. 25:1430, 1995
4. Bollaert, P-E., Charpentier, C., Levy, B., Debouverie, M., Audibert, G., and Larcan, A.: Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit. Care Med. 26:645, 1998
5. Casey, L.C., Balk, R.A., and Bone, R.C.: Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann. Intern. Med. 119:771, 1993
6. Ziegler, E.J., Fisher, C.J., Jr., Sprung, C.L., Straube, R.C., Sadoff, J.C., Foulke, G.E., Wortel, C.H., Fink, M.P., Dellinger, R.P., Teng, N.N.H., Allen, I.E., Berger, H.J., Knatterud, G.L., LoBuglio, A.F., and Smith, C.R.: Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. N. Engl. J. Med. 324:429, 1991
7. Luce, J.M.: Introduction of new technology into critical care practice: a history of HA-1A human monoclonal antibody against endotoxin. Crit. Care Med. 27:1233, 1993
8. McCloskey, R.V., Straube, R.C., Sanders, C., Smith, S.M., Smith, C.R., and CHESS Trial Study Group: Treatment of septic shock with human monoclonal antibody HA-1A: a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 121:1, 1994
9. Greenman, R.L., Schein, R.M.H., Martin, M.A., Wenzel, R.P., MacIntyre, N.R., and Emmanuel, G.: A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. J.A.M.A. 266:1097, 1991
10. Bone, R., Balk, R., Fein, A., Perl, T., Wenzel, R., Reines, H., Quenzer, R., Iberti, T., Macintyre, N., and Schein, R.: A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicentre, randomized, controlled trial. Crit. Care Med. 25:994, 1995
11. Willatts, S., Radford, S., and Leitermann, M.: Effects of the antiendotoxic agent, taurolidine, in the treatment of sepsis syndrome: a placebo-controlled, double-blind trial. Crit. Care Med. 25:1033, 1995
12. Beutler, B., and Grau, G.E.: Tumor necrosis factor in the pathogenesis of infectious diseases. Crit. Care Med. 21:S423, 1993
13. Abraham, E., Wunderink, R., Silverman, H., Perl, T., Nasraway, S., Levy, H., Bone, R., Wennzel, R., Balk, R., Allred, R., Pennington, J., and Wherry, J.: Efficacy and safety of monoclonal antibody to human tumour necrosis factor a in patients with sepsis syndrome: A randomized, controlled, double-blind, multicentre clinical trial. J.A.M.A. 273: 934, 1995
14. Cohen, J., Carlet, J., and INTERSEPT Study Group INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumour necrosis factor-a in patients with sepsis. Crit. Care Med. 24:1431, 1996
15. Abraham, E., Anzueto, A., Gutierrez, G., Tessler, S., San Pedro, G., Wunderink, R., Dal Nogare, A., Nasraway, S., Berman, S., Cooney, R., Levy, H., Baughman, R., Rumbak, M., Light, R.B., Poole, L., Allred, R., Constant, J., Pennington, J., Porter, S., and NORASEPT II Study Group: Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Lancet 351:929, 1998
16. Reinhart, K., Wiegand-Löhnert, C., Grimminger, F., Kaul, M., Withington, S., Treacher, D., Eckart, J., Willatts, S., Bouza, C., Krausch, D., Stockenhuber, F., Eiselstein, J., Daum, L., Kempeni, J., and MAK 195F Sepsis Study Group: Assessment of the safety and efficacy of the monoclonal anti-tumour necrosis factor antibody, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit. Care Med. 24:733, 1996
17. Fischer, C.J., Jr., Opal, S.M., Dhainaut, J-F., Stephens, S., Zimmerman, J.L., Nightingale, P., Harris, S.J., Schein, R.M., Panacek, E.A., Vincent, J.L., Falk, G.E., Warren, E.L., Garrard, C., Park, G., Bodmer, M.W., Cohen, J., van der Linden, C., Cross, A.S., Sadoff, J.C., and CB0006 Sepsis Study Group: Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis: the CB0006 Sepsis Syndrome Study Group. Crit. Care Med. 21:318, 1993
18. Vincent, J.L., Bakker, J., Marecaux, G., Schandene, L., Kahn, R.J., and Dupont, E.: Administration of anti-TNF antibody improves left ventricular function in septic shock patients: results of a pilot study. Chest 101:810, 1992
19. Clark, M.A., Plank, L.D., Connolly, A.B., Streat, S.J., Hill, A.A., Gupta, R., Monk, D.N., Shenkin, A., and Hill, G.L.: Effect of a chimeric antibody to tumour necrosis factor alpha on cytokine and physiologic responses in patients with severe sepsis: a randomized clinical trial. Crit. Care Med. 26:1650, 1998
20. Dhainaut, J-F., Vincent, J.L., Richard, C., Lejeune, P., Martin, C., Fierobe, L., Stephens, S., Nevy, U.M., and Sopworth, M.: CDP571, a humanized antibody to human tumour necrosis factor-α: safety, pharmacokinetics, immune response, and the influence of the antibody on cytokine concentrations in patients with septic shock. Crit. Care Med. 23:1461, 1995
21. Fisher, C.J., Agosti, J.M., Opal, S.M., Lowry, S.F., Balk, R.A., Sadoff, J.C., Abraham, E., Schein, R.M.H., Benjamin, E., and Soluble TNF Receptor Sepsis Study Group: Treatment of septic shock with the tumour necrosis factor receptor: Fc fusion protein. N. Engl. J. Med. 334:1697, 1996
22. Abraham, E., Glauser, M.P., Beutler, T., Garbino, J., Gelmont, D., Laterre, P.P., Kudsk, K., Bruining, H.A., Otto, C., Tobin, E., Zwingelstein, C., Lesslauer, W., Leighton, A., and Ro 45-2081 Study Group: p55 Tumour necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock: a randomized controlled multicenter trial. J.A.M.A. 277:1531, 1997
23. Dinarello, C.A., and Wolfe, S.M.: The role of interleukin-1 in disease. N. Engl. J. Med. 328:106, 1993
24. Fisher, C.J., Slotman, G.J., Opal, S.M., Pribble, J.P., Bone, R.C., Emmanuel, G., Ng, D., Bloedow, D.C., Catalano, M.A., and IL-1RA Sepsis Syndrome Study Group: Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit. Care Med. 22:12, 1994
25. Fischer, C., Dhainaut, J.F.A., Opal, S., Pribble, J., Balk, R., Slotman, G., Iberti, T., Rackow, E., Shapiro, M., Greenman, R., Reines, H., Shelly, M., Thompson, B., LaBrecque, J., Catalano, M., Knaus, W., and Sadoff, J.: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. J.A.M.A. 277:1836, 1994
26. Opal, S.M., Fisher, C.J., Dhainaut, J-F., Vincent, J.L., Brase, R., Lowry, S.F., Sadoff, J.C., Slotman, G.J., Levy, H., Balk, R.A., Shelly, M.P., Pribble, J.P., LaBreque, J.F., Lookabaugh, J., Donovan, H., Dubin, H., Baughman, R., Norman, J., DeMaria, E., Matzel, K., Abraham, E., Seneff, M., and Interleukin-1 Receptor Antagonist Sepsis Investigator Group: Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit. Care Med. 25:1115, 1997
27. Fein, A.M., Bernard, G.R., Criner, G.J., Fletcher, E.C., Good, J.T.J., Knaus, W.A., Levy, H., Matuschak, G.M., Shaines, H.M., Taylor, R.W., Rodell, T.C., and CP-0127 SIRS and Sepsis Study Group: Treatment of severe systemic inflammatory response syndrome with a novel bradykinin antagonist, Deltibant (CP-0127). J.A.M.A. 227:482, 1997
28. Fink, M.P.: Therapeutic options directed against platelet activating factor, eicosanoids and bradykinin in sepsis. J. Antimicrob. Chemother. 41(Suppl. A):81, 1998
29. Dhainaut, J-F., Tenaillon, A., Le Tulzo, Y., Schlemmer, B., Solet, J-P., Wolfe, M., Holzapfel, L., Zeni, F., Dreyfuss, D., Mira, J-P., de Vathaire, F., Guinot, P., and BN 52021 Sepsis Study Group: Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Crit. Care Med. 22:1720, 1994
30. Dhainaut, J.F., Tenaillon, A., Hemmer, M., Damas, P., Letulzo, Y., Radermacher, P., Schaller, M.D., Solet, J.P., Wolff, M., Holzapfel, L., Zeni, F., Motin, J., Mira, J., de Vathaire, F., Chrétien, J.M., Marsais, J., Gourlay, M.L., Guinot, P., and Sepsis Study Group: Confirming phase III clinical trial to study the efficacy of a PAF antagonist, BN 52021, in reducing mortality of patients with severe gram negative sepsis. Am. J. Respir. Crit. Care Med. 151:A447, 1995
31. Froon, A.M., Greve, J.W., Buurman, W.A., van der Linden, C.J., Langemeijer, H.J., Ulrich, C., and Bourgeois, M.: Treatment with the platelet-activating antagonist TCV-309 in patients with severe systemic inflammatory response syndrome: a prospective, multi-center, double-blind, randomized phase II trial. Shock 5:313, 1996
32. Bacher, A., Mayor, N., Klimscha, W., Oismüller, C., Steltzer, H., and Hammerle, A.: Effects of pentoxifylline on haemodynamics and oxygenation in septic and nonseptic patients. Crit. Care Med. 25:795, 1997
33. Staubach, K.H., Schröder, J., Stüber, F., Gehrke, K., Traumann, E., and Zabel, P.: Effect of pentoxifylline in severe sepsis: results of a randomized, double-blind, placebo-controlled trial. Arch. Surg. 133: 94, 1998
34. Ertel, W., Keel, M., Neidhardt, R., Steckholzer, U., Kremer, J-P., Ungenthuem, U., and Trentz, O.: Inhibition of the defence system stimulating interleukin-12 interferon-γ pathway during critical illness. Blood 89:1612, 1997
35. Docke, W.D., and Randow, F.: Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat. Med. 3:678, 1997
36. Johnson, M.L., and Billiar, T.R.: Roles of nitric oxide in surgical infection and sepsis. World J. Surg. 22:187, 1998
37. Avontuur, J.A.M., Tutein Nolthenius, R.P., van Bodegom, J.W., and Bruining, H.A.: Prolonged inhibition of nitric oxide synthesis in severe septic shock: a clinical study. Crit. Care Med. 26:660, 1998
38. Saito, H., Inoue, T., Fukatsu, K., Ming-Tsan, L., Inabu, T., Fukushima, R., and Muto, T.: Growth hormone and the immune response to bacterial infection. Horm. Res. 45:50, 1996
39. Koea, J.B., Breier, B.H., Douglas, R.G., Gluckman, P.D., and Shaw, J.H.F.: Anabolic and cardiovascular effects of recombinant human growth hormone in surgical patients with sepsis. Br. J. Surg. 83:196, 1996
40. Bettany, G.E., Camacho-Hubner, C., Obeid, O., Halliday, D., and Powell-Tuck, J.: Metabolic effects of adjuvant recombinant human growth hormone in patients with continuing sepsis receiving parenteral nutrition. JPEN J. Parenter. Enteral Nutr. 22:199, 1998
41. Voerman, H.J., Strack van Schijndel, R.J.M., Groeneveld, A.B.J., de Boer, H., Nauta, J.P., van der Veen, E.A., and Thijs, L.G.: Effects of recombinant human growth hormone in patients with severe sepsis. Ann. Surg. 216:648, 1992
42. Yarwood, G.D., Ross, R.J.M., Medbak, S., Coakley, J., and Hinds, C.J.: Administration of human recombinant insulin-like growth factor-I in critically ill patients. Crit. Care Med. 25:1352, 1997
43. Minard, G., and Kudsk, K.A.: Nutritional support and infection: does the route matter? World J. Surg. 22:213, 1998
44. Alexander, J.W., Ogle, C.K., and Nelson, J.: Diets and infection: composition and consequences. World J. Surg. 22:209, 1998
45. Atkinson, S., Sieffert, E., Bihari, D., and Guy's Hospital Intensive Care Group: A prospective, randomized, double-blind, controlled clinical trial of enteral immunonutrition in the critically ill. Crit. Care Med. 26:1164, 1998
46. Bower, R.H., Cerra, F.B., Bershadsky, B., Licarri, J.J., Hoyt, D.B., Jensen, G.L., van Buren, C.T., Rothkopf, M.M., Daly, J.M., and Adelsberg, B.R.: Early enteral administration of a formula (Impact®) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients: results of a multicenter, prospective, randomized, clinical trial. Crit. Care Med. 23:436, 1995
47. García-de-Lorenzo, A., Ortíz-Leyba, C., Planas, M., Montejo, J.C., Núñez, R., Ordóñez, F.J., Aragón, C., and Jiménez, F.J.: Parenteral administration of different amounts of branched-chain amino acids in septic patients: clinical and metabolic aspects. Crit. Care Med. 25:418, 1997
48. Griffiths, R.D., Jones, C., and Palmer, T.E.: Six-momh outcome of critically ill patients given glutamine-supplemented parenteral nutrition. Nutrition 13:295, 1997
49. Hill, A.G., and Hill, G.L.: Metabolic response to severe injury. Br. J. Surg. 85:884, 1998
50. Roth, E., Valentini, L., Semsroth, M., Hölzenbein, T., Winkler, S., Blum, W., Ranke, M.B., Schemper, M., Hammerle, A., and Karner, J.: Resistance of nitrogen metabolism to growth hormone treatment in the early phase after injury of patients with multiple injuries. J. Trauma 38:136, 1995
51. Behrman, S.W., Kudsk, K.A., Brown, R.O., Vehe, K.L., and Wojtysiak, S.L.: The effect of growth hormone on nutritional markers in enterally fed immobilized trauma patients. J.P.E.N. J. Parenter. Enteral Nutr. 19:41, 1995
52. Cioffi, W.G., Gore, D.C., Rue, L.R.I., Carrougher, G., Guler, H-P., McManus, W.F., and Pruitt, B.A.: Insulin-like growth factor-1 lowers protein oxidation in patients with thermal injury. Ann. Surg. 220:310, 1994
53. Polk, H.C., Cheadle, W.G., Livingston, D.H., Rodriguez, J-L., Starko, K.M., Izu, A.E., Jaffe, H.S., and Sonnenfeld, G.: A randomized prospective clinical trial to determine the efficacy of interferon-γ in severely injured patients. Am. J. Surg. 163:191, 1992
54. Dries, D.J., Jurkovich, G.J., Maier, R.V., Clemmer, T.P., Struve, S.N., Weigelt, J.A., Stanford, G.G., Herr, D.L., Champion, H.R., Lewis, F.R., Hoyt, D., Hansbrough, J., Yellin, A.E., Berne, T.V., Trunkey, D.D., Jaffe, H.S., Munera, C., Fisher, P., and Starko, K.M.: Effects of interferon gamma on infection-related deaths in patients with severe injury. Arch. Surg. 129:1031, 1994
55. Wasserman, D., Ioannovich, J.D., Hinzmann, R.D., Deichsel, G., Steinmann, G.G., and Burns Study Group: Interferon-γ in the prevention of severe burn-related infections: a European phase III multicenter trial. Crit. Care Med. 26:434, 1998
56. Pape, H.-C., Dwenger, A., Regel, G., Auf'm'Kolck, M., Gollub, F., Wisner, D., Sturm, J.A., and Tscherne, H.: Increased gut permeability after multiple trauma. Br. J. Surg. 81:850, 1994
57. Moore, F.A., Moore, E.E., Kudsk, K.A., Brown, R.O., Bower, R.H., Koruda, M.J., Baker, C.C., and Barbul, A.: Clinical benefits of an immune-enhancing diet for early postinjury enteral feeding. J. Trauma 37:607, 1994
58. Kudsk, K.A., Minard, G., Croce, M.A., Brown, R.O., Lowrey, T.S., Pritchard, F.E., Dickerson, R.N., and Fabian, T.C.: A randomized trial of isonitrogenous enteral diets alter severe trauma. Ann. Surg. 224:531, 1996
59. Mendez, C., Jurkovich, G.J., Garcia, I., Davis, D., Parker, A., and Maier, R.V.: Effects of an immune-enhancing diet in critically injured patients. J. Trauma 42:933, 1997
60. Saffte, J.R., Wiebke, G., Jennings, K., Morris, S.E., and Barton, R.G.: Randomized trial of immune-enhancing enteral nutrition in burn patients. J. Trauma 42:793, 1997
61. Hill, G.L., Douglas, R.G., and Schroeder, D.: Metabolic basis for the management of patients undergoing major surgery. World J. Surg. 17:146, 1993
62. Windsor, J., and Hill, G.: Protein depletion and surgical risk. Aust. N.Z.J. Surg. 58:711, 1988
63. Windsor, J.A., and Hill, G.L.: Risk factors for postoperative pneumonia: the importance of protein depletion. Ann. Surg. 208:209, 1988
64. Vara-Thorbeck, R., Guerrero, J.A., Ruiz-Requena, M.E., Capitán, J., Rodriguez, M., Rosell, J., Mekinassi, K., Maldonado, M., and Martin, R.: Effects of growth hormone in patients receiving total parenteral nutrition following major gastrointestinal surgery. Hepatogastroenterology 39:210, 1992
65. Vara-Thorbeck, R., Guerrero, J.A., Rosell, J., Ruiz-Requena, M.E., and Capitán, J.: Exogenous growth hormone: effects on the catabolic response to surgically produced acute stress and on postoperative immune function. World J. Surg. 17:530, 1993
66. Wong, W., Soo, K., Nambiar, R., Tan, Y.S., Yo, S.L., and Tan, I.K.: The effect of recombinant growth hormone on nitrogen balance in malnourished patients after major abdominal surgery. Aust. N.Z.J. Surg. 65:109, 1995
67. Jiang, Z-M., He, G-Z., Zhang, S-Y., Wang, X-R., Yang, N-F., Zhu, Y., and Wilmore, D.W.: Low-dose growth hormone and hypocaloric nutrition attenuate the protein-catabolic response after major operation. Ann. Surg. 210:513, 1989
68. Mealy, K., Barry, M., O'Mahony, L., Sheehan, S., Burke, P., McCormack, C., Whitehead, A.S., and Bouchier-Hayes, D.: Effects of human recombinant growth hormone (rhGH) on inflammatory responses in patients undergoing abdominal aneurysm repair. Intensive Care Med. 24:128, 1998
69. Leinsköld, T., Permert, J., Olaison, G., and Larsson, J.: Effect of post-operative insulin-like growth factor I supplementation on protein metabolism in humans. Br. J. Surg. 82:921, 1995
70. Sandström, R., Svanberg, E., Hyltander, A., Haglind, E., Ohlsson, C., Zachrisson, H., Berglund, B., Lindholm, E., Brevinge, H., and Lundholm, K.: The effect of recombinant human IGF-1 on protein metabolism in post-operative patients without nutrition compared to effects in experimental animals. Eur. J. Clin. Invest. 25:784, 1995
71. Souba, W.W.: Nutritional support. N. Engl. J. Med. 336:41, 1997
72. Fan, S-T., Lo, C-M., Lai, E.C.S., Chu, K-M., Lui, C-L., and Wong, J.: Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. N. Engl. J. Med. 331:1547, 1994
73. Heslin, M.J., Latkany, L., Leung, D., Brooks, A.D., Hochwald, S.N., Pisters, P.W.T., Shike, M., and Brennan, M.F.: A prospective, randomized trial of early enteral feeding after resection of upper gastrointestinal malignancy. Ann. Surg. 226:567, 1997
74. Senkal, M., Mumme, A., Eickhoff, U., Geier, B., Späth, G., Wulfert, D., Joosten, U., Frei, A., and Kemen, M.: Early postoperative enteral immunonutrition: clinical outcome and cost-comparison analysis in surgical patients. Crit. Care Med. 25:1489, 1997
75. Kemen, M., Senkal, M., Homann, H.H., Mumme, A., Dauphin, A.K., Baire, J., Windeler, J., Neumann, H., and Zumtobel, V.: Early postoperative enteral nutrition with arginine-omega-3 fatty acids and ribonucleic acid-supplemented diet verse placebo in cancer patients: an immunologic evaluation of Impact. Crit. Care Med. 23:652, 1995